Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VSJ 110

Next Previous
Drug Profile

VSJ 110

Alternative Names: CFTRact-K267; VSJ-110

Latest Information Update: 22 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Vanda Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Diamines; Eye disorder therapies; Fluorinated hydrocarbons; Small molecules; Triazines
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 17 Sep 2025 Vanda Pharmaceuticals initiates a phase II trial in Dry eyes in USA (Ophthalmic, Liquid) (NCT07179055)
  • 29 Feb 2024 Phase-II clinical trials in Dry eyes in USA (Ophthalmic) (NCT06296966)
  • 26 Dec 2022 Phase-II development is ongoing in Allergic conjunctivitis in USA (Ophthalmic) (NCT04622345)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top